4 Results for "

SAR optimization

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "SAR optimization" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-153083
Target:  

mRNA SARS-CoV

Research Areas:  

Infection

COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) is an mRNA encoding the SARS-CoV-2 spike protein with enhanced performance via chemical modification. COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) replaces natural uridine (UTP) with N1-Me-Pseudo UTP, which effectively reduces immunogenicity and improves stability and translation efficiency. The 3' UTR of COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) optimizes AU-rich elements through HuR anchor sites, exhibiting higher translation efficiency. COVID-19 Spike Protein mRNA is widely used in COVID-19-related scientific research and vaccine development .
loading...
    loading...
Cat. No.: HY-L927
9,955 compounds

Designed to maximize efficiency in hit discovery and optimization, this compound library is built on a foundation of diverse Bemis-Murcko scaffolds, with each scaffold is represented by two specifically derived molecules. This strategy ensures broad chemical space through scaffold diversity while enabling preliminary functional group exploration. This approach provides early structure-activity relationship (SAR) insights for every scaffold, making it a valuable tool for accelerating drug discovery.

Cat. No.: HY-189662
Research Areas:  

Infection

Y-U0-S is a potent inhibitor of the coronavirus main protease (M pro) and host cathepsins. The IC50 values of Y-U0-S against SARS-CoV-2 M pro, SARS-CoV Mpro, Cathepsin B, and Cathepsin L are 0.81, 1.14, 0.86, and 21.13 μM, respectively. Y-U0-S exhibits broad-spectrum anti-coronavirus activity, with an EC50 of 0.22 μM against wild-type SARS-CoV-2. Y-U0-S forms an irreversible covalent bond with the catalytic site C145 of M pro through its aldehyde warhead, and by optimizing multi-site occupancy of the scaffold to engage conserved residues, it effectively blocks enzyme activity and inhibits viral replication. Y-U0-S can be used for research on COVID-19 .
loading...
    loading...
Cat. No.: HY-L245
2,248 compounds

At the forefront of innovative drug discovery, every medicinal chemist faces the challenge of rapidly identifying high-quality hit compounds from vast repositories of chemical resources.

The MCE Natural Product Diversity Scaffold Library is the result of a streamlined optimization process built upon our existing natural product collection. Adhering to the rigorous selection principle of "retaining only one representative compound per BMS scaffold", we have concentrated the diversity of thousands of compounds into a high-value, low-redundancy core set containing 2,248 compounds. All compounds are derived from natural sources, inheriting their inherent advantages of structural complexity and drug-likeness. By eliminating redundancy, the library size is significantly reduced without any compromise to chemical diversity. This approach effectively lowers the cost and time required for primary screening while simplifying downstream data analysis and structure-activity relationship (SAR) studies.